FDA expands use of Xgeva to include giant cell tumor of the bone

06/14/2013 | Medscape (free registration)

The FDA approved the use of Amgen's Xgeva, or denosumab, to treat adults and some adolescents with giant cell tumor of the bone when surgery is not an option. The decision makes denosumab the first approved drug for this condition. Xgeva, a fully human monoclonal antibody, was previously approved for treatment of osteoporosis and for prevention of skeletal-related events in adults with bone metastases and solid tumors.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC